Item 4.2 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review



On May 16, 2023, the Audit Committee of the Board of Directors (the "Audit
Committee") and management (the "Management") of MedMen Enterprises Inc. (the
"Company", "we", "us", "our") concluded that a restatement of the Company's
previously issued (i) audited consolidated financial statements included in the
Company's Annual Report on Form 10-K for the fiscal year ended June 25, 2022,
filed with the Securities and Exchange Commission (the "SEC") on September 9,
2022 (the "2022 Form 10-K"), and (ii) unaudited interim consolidated financial
statements included in the Company's Quarterly Report on Form 10-Q for the
period ended December 24, 2022, filed with the SEC on February 2, 2023 (the "Q2
2023 Form 10-Q" and together with the 2022 Form 10-K, the "Prior Reports" and
the fiscal periods covered thereby the "Prior Periods") would be required to
correct certain errors reflected in the Prior Reports as described below. In
addition, a restatement of the audited consolidated balance sheet as of the
fiscal year ended June 25, 2022 included in the Company's Quarterly Report on
Form 10-Q for the period ended September 24, 2022, filed with the SEC on
November 3, 2022 (the "Q1 2023 Form 10-Q"), would also be required to correct
the errors as described below. Accordingly, neither the Company's previously
issued audited consolidated financial statements as of and for the fiscal year
ended June 25, 2022 and unaudited consolidated financial statements as of and
for the six months ended December 24, 2022 nor the previously issued audited
consolidated balance sheet as of the fiscal year ended June 25, 2022 as
reflected in the Q1 2023 Form 10-Q should be relied upon. The Audit Committee
and Management discussed the matters disclosed herein with MNP LLP, the
Company's former independent registered public accounting firm (the "Predecessor
Auditor"), and with Marcum LLP, the Company's current independent registered
public accounting firm (the "Successor Auditor").

In connection with the Company's process in preparing its financial statements
for the periods ended September 24, 2022, December 24, 2022 and March 25, 2023,
Management identified errors related to impairment expenses that should have
been disclosed in the footnotes of the financial statements for the Prior
Periods. In addition, Management also identified errors related to general and
administrative expenses, cost of goods sold and depreciation and amortization
expense. The errors in general and administrative expenses related to accrued
expenses that had been paid for and the accrual was not released causing a
duplicate expense recorded. The error in cost of goods sold related to an
accumulation of discrepancies in the reconciliation of intercompany transactions
resulting in duplicate expenses in cost of goods sold. The errors in
depreciation and amortization related to termination of leases that continued to
be depreciated after the termination date.

The adjustments below are the Company's current good faith estimates pending the
completion of the Company's account reconciliation control through the fiscal
year ended July 1, 2023 and any audit procedures the Successor Auditor is
required to perform on the error corrections impacting each of the Prior
Reports.

The net impact of these estimated adjustments on the Company's audited consolidated statement of operations for the fiscal year ended June 25, 2022 is expected to be approximately as follows (in millions):



                                                               Amount of 

Error When Corrected Will


                Description of Error                     (Decrease) 

Increase Corresponding Statement of


                                                                     Operations Line Caption
Overstatement of cost of goods sold                   $                                               (3.7)
Overstatement of general and administrative expenses  $                                               (3.4)
Overstatement of depreciation and amortization        $                                               (1.5)
Understatement of impairment expense                  $                                                 3.7
Impact on net loss from continuing operations         $                                               (4.9)
Impact on net loss from discontinuing operations      $                                                 1.5
Impact on net loss                                    $                                               (3.4)


                                       1

--------------------------------------------------------------------------------

As a result of the estimated total adjustments included above, the Company noted
that corresponding adjustments to its audited consolidated balance sheet as of
June 25, 2022 as reflected in the Company's 2022 Form 10-K, Q1 2023 Form 10-Q
and Q2 2023 Form 10-Q were necessary as follows (in millions):

                                                               Amount of Error When Corrected Will
Description of Error                                  (Decrease) Increase 

Corresponding Balance Sheet Line

Caption


Overstatement of other current assets                 $                                               (1.1)
Overstatement of operating leases right-of-use assets $                                               (4.8)
Overstatement of property and equipment, net          $                                               (3.1)
Understatement of intangible assets, net              $                                                 5.2
Understatement of other non-current assets            $                                                 1.2
Overstatement of accounts payable and accrued         $                                               (5.8)

expenses


Overstatement of accumulated deficit                  $                                                 3.4


The net impact of these estimated adjustments on the Company's unaudited interim
consolidated statement of operations for the three months ended December 24,
2022 is expected to be approximately as follows (in millions):

                                                               Amount of Error When Corrected Will
Description of Error                                     (Decrease) 

Increase Corresponding Statement of


                                                                     Operations Line Caption
Overstatement of cost of goods sold                   $                                               (3.7)
Overstatement of general and administrative expenses  $                                               (0.4)
Understatement of impairment expense                  $                                                 3.6
Impact on net loss from continuing operations         $                                               (0.5)
Impact on net loss                                    $                                               (0.5)


The net impact of these estimated adjustments on the Company's unaudited interim
consolidated statement of operations for the six months ended December 24, 2022
is expected to be approximately as follows (in millions):

                                                               Amount of Error When Corrected Will
Description of Error                                     (Decrease) 

Increase Corresponding Statement of


                                                                     Operations Line Caption
Overstatement of cost of goods sold                   $                                               (3.7)
Overstatement of general and administrative expenses  $                                               (0.4)
Understatement of impairment expense                  $                                                 4.1
Impact on net loss from continuing operations         $                                                   -
Impact on net loss                                    $                                                   -


The Company intends to reflect the restatement of the Prior Periods in
amendments to its Prior Reports and the Q1 2023 Form 10-Q, which the Company
intends to file as soon as reasonably practicable. The Company is required to
file its Form 10-Q for the period ended March 25, 2023 on or about the same time
the Company files its Form 10-K for the fiscal year ending July 1, 2023, which
will allow the Successor Auditor to perform its required audit procedures on the
errors that occurred in a fiscal year audited by the Predecessor Auditor. At
this time, the Company does not plan to amend any other previously filed reports
as a result of the matters identified in this Current Report on Form 8-K. The
restatement does not impact the Company's current cash position, cash flow or
liquidity.

As fully described in the Company's 2022 Form 10-K, Management identified a
material weakness in the Company's internal control over financial reporting
during the fiscal year ended June 25, 2022 specific to its account
reconciliation process (the "Material Weakness") and determined that the
Company's internal control over financial reporting was not effective as of June
25, 2022. It is in the execution of the measures implemented by the Company's
management to remediate the Material Weakness that the error corrections
disclosed herein were identified. However, the Material
                                       2
--------------------------------------------------------------------------------

Weakness will not be considered fully remediated until the new remediation control procedures are implemented for a sufficient period of time and Management has concluded that these controls are operating effectively as designed.



The preliminary evaluation provided above is subject to the completion of the
Company's restatement analysis and financial close and reporting process. While
the Company believes that the foregoing description fairly represents the
expected impact of the restatement on the Company's results of operations for
the Prior Periods, additional material weaknesses may be identified, further
adjustments may arise, including with respect to changes on the Company's
balance sheet, and the restated financial statements for the Prior Periods will
reflect any such additional adjustments.

Forward-Looking Statements



This Current Report on Form 8-K includes "forward-looking statements," which may
be identified by the use of words such as "anticipates," "will," "believes,"
"intends," "plans," "expects" and other similar words and expressions that
predict or indicate future events or trends that are not statements of
historical matters. These forward-looking statements include statements and
expectations about the Company's results, identification of errors in previous
filings and the timing and impact thereof; the anticipated impact of certain
accounting errors and related matters on our results of operations and financial
condition; the scope and number of material weaknesses in internal control over
financial reporting and their potential impact; and the anticipated future
performance of our businesses. Forward-looking statements are based on
information available at the time those statements are made and/or management's
good faith belief as of that time with respect to future events, and are subject
to risks and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-looking
statements. Such risks and uncertainties include, without limitation, risks
related to the timely and correct completion of the restatement and related
filings; identification of errors in our financial reporting in the future that
require us to restate previously issued financial statements, which may subject
us to unanticipated costs or regulatory penalties and could cause investors to
lose confidence in the accuracy and completeness of our financial statements;
the risk that additional information may become known prior to the expected
filing with the SEC of the periodic reports described herein or that other
subsequent events may occur that would require the Company to make additional
adjustments to its financial statements or delay the filing of the corrected or
future periodic reports with the SEC; risks related to changes in the effects of
the restatement on the Prior Reports or financial results; risks related to
higher than expected charges after completing the restatement process; risks
related to delays in the filing of the Company's Quarterly Report on Form 10-Q
for the period ended March 25, 2023; risks related to our ability to implement
and maintain effective internal control over financial reporting in the future,
which may adversely affect the accuracy and timeliness of our financial
reporting; risks related to the Company's plans to remediate any control and
procedures deficiencies; risks related to the timing and results of the
Company's review of the effectiveness of internal control over financial
reporting and related disclosure controls and procedures; our ability to become
current with our SEC periodic reporting requirements; our ability to effectively
implement our business strategies and manage the risks in our business; the
reactions of the marketplace to the foregoing; litigation and potential
governmental investigations or proceedings arising out of or related to
accounting and financial reporting matters; general business, economic and
political conditions as well as those risks and uncertainties described in the
sections entitled "Risk Factors" in the Company's most recent Annual Report on
Form 10-K filed with the SEC and similar disclosures in subsequent periodic and
current reports filed with the SEC, which are available on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on which they are
made. The Company disclaims any obligation to update or correct any
forward-looking statements made herein due to the occurrence of events after the
issuance of this report except as required under federal securities laws.


Item 9.01 Financial Statements and Exhibits

(d) Exhibits



Exhibit Number                    Description
                                  Cover Page Interactive Data File (embedded within the Inline XBRL
104                               document)


                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses